{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=PTCL", "query": { "condition": "PTCL" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 70, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=PTCL&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-22T14:26:24.785Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00005080", "title": "506U78 in Treating Patients With Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Small Intestine Lymphoma", "Stage I Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage I Mycosis Fungoides/Sezary Syndrome", "Stage II Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage II Mycosis Fungoides/Sezary Syndrome", "Stage III Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage III Mycosis Fungoides/Sezary Syndrome", "Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage IV Mycosis Fungoides/Sezary Syndrome" ], "interventions": [ { "name": "nelarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "69 Years", "sex": "ALL", "summary": "Up to 69 Years" }, "enrollment_count": 74, "start_date": "2000-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-16", "last_synced_at": "2026-07-22T14:26:24.785Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005080" }, { "nct_id": "NCT03161223", "title": "Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma, T-Cell" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Pralatrexate", "type": "DRUG" }, { "name": "Romidepsin", "type": "DRUG" }, { "name": "5-Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 148, "start_date": "2018-05-30", "completion_date": "2023-02", "has_results": false, "last_update_posted_date": "2022-03-31", "last_synced_at": "2026-07-22T14:26:24.785Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03161223" }, { "nct_id": "NCT06561048", "title": "Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Peripheral T-Cell Lymphoma, Not Otherwise Specified", "Angioimmunoblastic T-cell Lymphoma", "Follicular T-Cell Lymphoma", "Nodal Peripheral T-Cell Lymphoma With TFH Phenotype", "Systemic Anaplastic Large Cell Lymphoma", "Lymphoma, T-Cell, Peripheral", "Lymphoma, T-Cell" ], "interventions": [ { "name": "Soquelitinib", "type": "DRUG" }, { "name": "Belinostat", "type": "DRUG" }, { "name": "Pralatrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corvus Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2024-10-02", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-04-08", "last_synced_at": "2026-07-22T14:26:24.785Z", "location_count": 21, "location_summary": "Duarte, California • Irvine, California • San Francisco, California + 16 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06561048" }, { "nct_id": "NCT01994382", "title": "Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Follicular Lymphoma (FL/Indolent NHL)", "Aggressive NHL (a NHL)", "Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)", "T-cell Lymphoma (PTCL and CTCL)", "B-cell Non Hodgkin Lymphoma (NHL)" ], "interventions": [ { "name": "Cerdulatinib", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Alexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2013-08-30", "completion_date": "2020-12-15", "has_results": true, "last_update_posted_date": "2022-04-05", "last_synced_at": "2026-07-22T14:26:24.785Z", "location_count": 23, "location_summary": "Huntsville, Alabama • Gilbert, Arizona • Los Angeles, California + 20 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01994382" }, { "nct_id": "NCT00632827", "title": "Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Peripheral T-Cell Lymphoma" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Navelbine", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride Liposome Injection", "type": "DRUG" }, { "name": "Granulocyte-colony stimulating factor (G-CSF)", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Carmustine", "type": "DRUG" }, { "name": "Denileukin diftitox", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 21, "start_date": "2008-07-01", "completion_date": "2016-06-23", "has_results": true, "last_update_posted_date": "2020-04-27", "last_synced_at": "2026-07-22T14:26:24.785Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00632827" }, { "nct_id": "NCT00865969", "title": "Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Peripheral T-cell Lymphoma" ], "interventions": [ { "name": "Belinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Spectrum Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 129, "start_date": "2008-12-15", "completion_date": "2014-10-27", "has_results": true, "last_update_posted_date": "2021-10-29", "last_synced_at": "2026-07-22T14:26:24.785Z", "location_count": 42, "location_summary": "Duarte, California • La Verne, California • Palm Springs, California + 33 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Verne", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Trumbull", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00865969" }, { "nct_id": "NCT04234048", "title": "Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "T-cell Lymphoma", "Cutaneous/Peripheral T-Cell Lymphoma", "Peripheral T-cell Lymphoma", "Peripheral T-Cell Lymphoma, Not Classified", "Primary Cutaneous T-cell Lymphoma", "Cutaneous T-Cell Lymphoma, Unspecified", "Cutaneous T-cell Lymphoma", "Follicular T-Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Sézary's Disease", "Mycosis Fungoides" ], "interventions": [ { "name": "Fenretinide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SciTech Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2023-12-18", "completion_date": "2027-05-01", "has_results": false, "last_update_posted_date": "2025-09-22", "last_synced_at": "2026-07-22T14:26:24.785Z", "location_count": 10, "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04234048" }, { "nct_id": "NCT02567656", "title": "Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, T-Cell, Peripheral", "Lymphoma, T-Cell, Cutaneous" ], "interventions": [ { "name": "RP6530", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rhizen Pharmaceuticals SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2015-09", "completion_date": "2018-12-10", "has_results": true, "last_update_posted_date": "2020-01-13", "last_synced_at": "2026-07-22T14:26:24.785Z", "location_count": 8, "location_summary": "Duarte, California • Orange, California • Aurora, Colorado + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02567656" }, { "nct_id": "NCT02464228", "title": "Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed or Refractory Peripheral T-Cell Lymphoma" ], "interventions": [ { "name": "Tipifarnib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kura Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2016-02-25", "completion_date": "2021-03-31", "has_results": true, "last_update_posted_date": "2024-06-26", "last_synced_at": "2026-07-22T14:26:24.785Z", "location_count": 5, "location_summary": "Palo Alto, California • New Haven, Connecticut • Tampa, Florida + 2 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02464228" }, { "nct_id": "NCT03947255", "title": "A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin Lymphoma", "Peripheral T Cell Lymphoma", "Anaplastic Large Cell Lymphoma" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2019-10-28", "completion_date": "2022-11-06", "has_results": true, "last_update_posted_date": "2023-10-13", "last_synced_at": "2026-07-22T14:26:24.785Z", "location_count": 19, "location_summary": "Anaheim, California • Lafayette, Colorado • Pembroke Pines, Florida + 14 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Lafayette", "state": "Colorado" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Elk Grove Village", "state": "Illinois" }, { "city": "Maywood", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03947255" } ] }